Latest News


Each news article below shows only part of the news story. To view the full story, click on Read More below the story. 

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • November 13, 2019 3:26 PM | Becca Liebers (Administrator)

    APAOG Member Benefits

    With over 250 members, the Association for Physician Assistants in Obstetrics and Gynecology is the only professional association devoted exclusively to PAs practicing in women's health. Established in 1991, APAOG is the collective voice for professionals working to improve the health care of women.

    APAOG commitment to its members:

    • To advocate for patient autonomy through education and collaborative care.
    • To promote clinical and academic excellence for members of APAOG.
    • To provide members with a forum to discuss topics that relate to PA's practicing in women's health.
    • To assist and support PA's and the healthcare team by providing information through education and programs relating to the delivery of quality women's healthcare services.

    Benefits of Membership 

    Download an APAOG Membership Flyer Here

    JOIN or Renew Today!
  • October 06, 2019 1:07 PM | Becca Liebers (Administrator)

    October 6-12, AAPA

    Every year from October 6-12, we celebrate National PA Week, which recognizes the PA profession and its contributions to the nation’s health.

    This week is also an opportunity to raise awareness and visibility of the profession. Before it was a week-long event, National PA Day was first celebrated on October 6, 1987, in honor of the 20th anniversary of the first graduating class of PAs from the Duke University PA program. October 6 is also the birthday of the profession’s founder, Eugene A. Stead, Jr., MD.

    More information here!

    Visit along on our facebook page

  • August 26, 2019 3:38 PM | Becca Liebers (Administrator)

    August 25, 2019 - MedPage Today

    Per the final two-part recommendation published at the USPSTF website and in JAMA, assessments for increased risk of BRCA1 and BRCA2 genetic mutations should be conducted in women who have a personal or family history of certain types of cancers (breast, ovarian, fallopian tube, or peritoneal cancers), or who have an ancestry associated with BRCA1 or BRCA2 mutations. Women found to be at increased risk should receive genetic counseling and, if indicated after counseling, BRCA testing. The first part of the recommendation received a 'B' grade, meaning a "high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial."

    Read More.

  • July 03, 2019 8:28 AM | Grant Dvorak (Administrator)

    July 3, 2019, Healthcare Business  

    Breast cancer is the second-most common cancer among women in the United States. Last year approximately 268,000 new cases of breast cancer were diagnosed in the U.S., and more than 40,000 women died of the disease. When breast cancer is found early, the five-year survival rate is 96%. If not identified until more advance stages (e.g., stage 4), the five-year survival rate drops to 16%. The key to survival is early detection.  

    Read more.

  • July 03, 2019 8:26 AM | Grant Dvorak (Administrator)

    July 3, 2019, MedPage Today 

    Updates to recommendations for hepatitis A and meningococcal vaccines were approved, while recommendations for the influenza vaccine remained unchanged, after the CDC's Advisory Committee for Immunization Practices (ACIP) meeting in Atlanta. Committee members also voted unanimously to leave the current recommendation for influenza vaccination as is. The annual influenza vaccine should continue to be offered to everyone 6 months or older who do not have contraindications. 

    Read more.

  • July 02, 2019 8:48 AM | Grant Dvorak (Administrator)

    July 2, 2019, MedPage Today 

    The appearance of simple ovarian cysts was common in premenopausal and postmenopausal women undergoing pelvic ultrasonography but was not associated with an increased risk of malignant ovarian cancer, researchers found. 

    Read more.

  • July 02, 2019 8:38 AM | Grant Dvorak (Administrator)

    July 2, 2019, MedPage Today 

    Breast density status should not be used as a stand-alone risk factor to refer women for supplemental imaging discussions, according to a new study. Instead, a combined approach using both breast density and Breast Cancer Surveillance Consortium (BCSC) 5-year risk score would identify those women at the highest risk for advanced cancer, said Karla Kerlikowske, MD, of the Department of Veterans Affairs in San Francisco, and colleagues.

    Read more.

  • July 01, 2019 12:46 PM | Grant Dvorak (Administrator)

    July 1, 2019, Pharmacy Times 

    Officials with the U.S. Food and Drug Administration have approved bevacizumab-bvzr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin), for the treatment of five types of cancer, according to a press release. Bevacizumab-bvzr is indicated for the treatment of metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma (RCC); and persistent, recurrent or metastatic cervical cancer. 

    Read more.

  • July 01, 2019 12:42 PM | Grant Dvorak (Administrator)

    July 1, 2019, Medscape 

    Fewer than 40% of people in the United States have ever been tested for HIV, according to a report from the Centers for Disease Control and Prevention published June 27 in Morbidity and Mortality Weekly Report.

    National HIV Testing Day, on June 27, acknowledges the vital role of testing in preventing, detecting, and treating HIV infection. Early diagnosis is critical to controlling transmission. Those who test negative but are at elevated risk can employ preexposure prophylaxis.

    Since 2006, CDC has recommended universal screening for HIV infection at least once in a healthcare setting for people aged 13 to 64 years and at least annual rescreening of individuals at increased risk. 

    Read more.

  • June 30, 2019 11:28 AM | Grant Dvorak (Administrator)

    June 30, 2019, MedPage Today 

    Use of intracytoplasmic sperm injection (ICSI) in cases without male infertility held no advantages over conventional in vitro fertilization (IVF), according to a pair of retrospective European studies. 

    Read more.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
Powered by Wild Apricot Membership Software